APRECAP-125/80 CAP

Description

APRECAP-125/80 CAP contains Aprepitant, an NK1 receptor antagonist, formulated in a combination pack with one 125 mg capsule and two 80 mg capsules. It is used as part of a combination antiemetic regimen to prevent acute and delayed nausea and vomiting caused by highly or moderately emetogenic chemotherapy. Aprepitant works by blocking the action of neurokinin-1, a substance in the brain involved in triggering nausea and vomiting. This therapy is typically administered as a 3-day regimen: 125 mg on Day 1 (prior to chemotherapy) followed by 80 mg on Days 2 and 3.

Key Features:

• Effective prevention of chemotherapy-induced nausea and vomiting (CINV)

• Contains 1 capsule of 125 mg and 2 capsules of 80 mg Aprepitant

• Typically used with a corticosteroid and a 5-HT3 antagonist (e.g., ondansetron)

• Well-tolerated, improves patient comfort during cancer treatment

• To be taken under strict medical supervision